- Previous Close
59.00 - Open
59.00 - Bid 59.00 x --
- Ask 60.00 x --
- Day's Range
58.00 - 60.00 - 52 Week Range
50.00 - 86.00 - Volume
616,700 - Avg. Volume
4,121,649 - Market Cap (intraday)
202.699B - Beta (5Y Monthly) -0.03
- PE Ratio (TTM)
-- - EPS (TTM)
-1.95 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
PT Royal Prima Tbk provides private hospital services in Indonesia. The company operates its hospitals under the Royal Prima Medan, Royal Prima Jambi, and RSU Royal Prima Marelan names. It provides health services, such as emergency, outpatient, inpatient, laboratorium, radiology, medical rehab, pharmacy, and MCU; and general surgery, internist, VCT, ICU, cardiology, urology, haemodialysis, maternity, paediatric care, endoscopy, endoscopy, cath lab, stroke centre, and trauma centre. The company's other services include acupuncture, anaesthesia, beauty and wellness, dermatology, dental and mouth, endocrine, digestive, vascular, neurology, ENT, haematology, nephrology, nutrient, consultancy, oncology, plastic and paediatric surgery, neurosurgery, obgyn and fertilization, ophthalmology, chemotherapy, psychiatrist, psychology, pulmonology, orthopaedic, and paediatric orthopaedic. PT Royal Prima Tbk was founded in 2013 and is headquartered in Jakarta, Indonesia.
www.royalprima.com784
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: PRIM.JK
View MorePerformance Overview: PRIM.JK
Trailing total returns as of 2/24/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PRIM.JK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PRIM.JK
View MoreValuation Measures
Market Cap
199.32B
Enterprise Value
134.92B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.67
Price/Book (mrq)
0.21
Enterprise Value/Revenue
0.45
Enterprise Value/EBITDA
160.42
Financial Highlights
Profitability and Income Statement
Profit Margin
-2.21%
Return on Assets (ttm)
-0.50%
Return on Equity (ttm)
-0.68%
Revenue (ttm)
297.89B
Net Income Avi to Common (ttm)
-6.59B
Diluted EPS (ttm)
-1.95
Balance Sheet and Cash Flow
Total Cash (mrq)
23.85B
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
44.39B